Nightingale Health’s technology used to analyze Uganda’s General Population Cohort (GPC)

Press release, 19 March 2024 at 8:00 a.m. (EET)

Nightingale Health Plc (“Nightingale Health”), a pioneer in health risk detection and preventative health, has entered into an agreement in which it will analyze blood samples from Uganda’s General Population Cohort (GPC). The GPC is a population-based study of approximately 22,000 individuals residing in southwestern Uganda. The study represents ten ethnolinguistic groupings and is the first from the region to be analyzed by Nightingale Health’s technology.

It has been widely suggested that ethnic differences play a role in the development of chronic diseases due to genetic background. However, environmental exposures, such as diet, which can be comprehensively measured with Nightingale Health’s metabolic biomarkers may play an even more significant role when it comes to the development of multiple different diseases.

“We are excited to collaborate with Nightingale Health and use their biomarker analysis technology in our Uganda Genome Resource Project bio-samples from Uganda’s General Population Cohort. By using Nightingale Health's expertise, we hope to better understand the metabolic profiles and the complex relationship between genetics, environment, and disease risk factors in Uganda population,” says Principal Investigator Professor Segun Fatumo, PhD.

During the past years Nightingale Health has been chosen as an analysis service provider for various studies with different ethnicities. Examples of such studies include the Singapore Multiethnic Cohort, China Kadoorie Biobank, and Mexico City Prospective Study. With this agreement Nightingale Health expands the use of its analysis technology to a new continent.

“We at Nightingale Health strive to make our services available for scientists around the globe. It is crucial for biomedicine to have metabolic biomarker data measured from individuals in as many parts of the world as possible. We are delighted that this study has chosen Nightingale Health’s analysis for their next stage of research,” says Jeffrey Barrett, Nightingale Health’s Chief Scientific Officer.

Nightingale Health’s technology has been used in population studies and large biobanks for several years with the number of samples analyzed totaling over 2 million. The results analyzed from each blood sample include 250 biomarkers, of which 39 are clinically validated and can be used in the same way as traditional clinical biomarkers. The biomarkers analyzed from a single blood sample in one measurement cover a wide range of biological functions, including lipids (e.g., LDL cholesterol, HDL cholesterol, triglycerides, ApoA1, and ApoB), insulin sensitivity (amino acids), dietary intake (e.g., omega-3 and omega-6 fatty acids), chronic inflammation (GlycA), fluid balance (e.g., albumin), and kidney function (e.g., creatinine).

For further information, please contact:

Teemu Suna, CEO
[email protected]

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com